NKTR
Nektar TherapeuticsNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.15B
P/E Ratio
—
EPS
$-9.73
Beta
1.18
52W High
$78.81
52W Low
$7.92
50-Day MA
$63.02
200-Day MA
$47.81
Dividend Yield
—
Profit Margin
-297.10%
Forward P/E
34.01
PEG Ratio
0.31
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Fundamentals
| Revenue (TTM) | $55.23M |
| Gross Profit (TTM) | $55.23M |
| EBITDA | $-129.75M |
| Operating Margin | -87.50% |
| Return on Equity | -217.90% |
| Return on Assets | -28.00% |
| Revenue/Share (TTM) | $3.27 |
| Book Value | $4.41 |
| Price-to-Book | 24.57 |
| Price-to-Sales (TTM) | 39.00 |
| EV/Revenue | 37.06 |
| EV/EBITDA | 3.51 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -25.30% |
| Shares Outstanding | $28.69M |
| Float | $26.95M |
| % Insiders | 0.57% |
| % Institutions | 61.09% |
Analyst Ratings
Consensus ($128.12 target)
1
Strong Buy8
Buy1
HoldData last updated: 4/9/2026